Abstract:Abstract Background MET amplification (amp) is a resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). Tepotinib (TEP), an oral, selective MET TKI, has shown promising antitumor activity in combination with gefitinib (GEF) in patients with MET+ EGFR-mutant NSCLC and acquired resistance to 1st-line EGFR TKIs in a phase 1b/2 study (NCT01982955). In the phase 1b part of the study, 4/6 patients with METamp had an objective response with TEP+GEF (67%). Methods In the phase 2 part of the study, Asian patients with advanced MET+ (MET2+ or 3+ by immunohistochemistry and/or METamp by in-situ hybridization) EGFR-mutant T790M- NSCLC and acquired resistance to 1st-line EGFR TKIs were randomized to receive oral TEP 500 mg + GEF 250 mg once daily or platinum + pemetrexed chemotherapy (CTx). The primary endpoint was investigator-assessed PFS. Secondary endpoints included PFS by independent review committee (IRC), overall response rate (ORR), and safety. Data from a minimum follow-up of 6-months are presented (cut-off 26 Mar 2018) for the pre-planned analysis of patients with METamp, defined as gene copy number (GCN) ≥5 and/or MET/CEP7 ratio ≥2. Results Low recruitment halted enrolment into phase 2. From 24 Apr 2015 to 12 Jun 2017, 55/156 planned patients were enrolled; 19 had METamp (TEP+GEF, 12; CTx, 7) and are included in this analysis. Median age of METamp patients was 60.4 years (range 42-74), 6 were men, 13 were never smokers, 5 had ECOG PS 0 and 14 had PS 1. Median GCN was 8.8 (range 4.8-29.5); 18 patients had GCN ≥5, 13 had MET/CEP7 ratio ≥2. Median TEP+GEF treatment duration was 37 weeks (range 4.6-91.9) and 4 patients are still receiving treatment, ongoing for ≥18 months. Investigator-assessed PFS improved with TEP+GEF vs CTx (mPFS 21.2 vs 4.2 months; HR 0.17 [90% CI 0.05, 0.57]), as well as IRC-assessed PFS (19.8 vs 5.5 months; HR 0.25 [90% CI 0.07, 0.85]). ORR also improved with TEP+GEF (investigator: 66.7% vs 42.9%; OR 2.67 [90% CI 0.37, 19.56] and IRC: 75.0% vs 42.9%; OR 4.00 [90% CI 0.51, 31.38]). Disease control was achieved in 11 (91.7%) patients receiving TEP+GEF vs 5 (71.4%) patients receiving CTx. Related grade ≥3 treatment-emergent adverse events (TEAEs) were reported in 6 (50.0%) patients receiving TEP+GEF and 5 (71.4%) patients receiving CTx. The most common related TEAEs in the TEP+GEF arm were diarrhea (TEP+GEF 50.0% vs CTx 14.3%) and amylase increased (TEP+GEF 41.7% vs CTx 0%) and in the CTx arm were anemia (TEP+GEF 0% vs CTx 57.1%), white blood cell count decreased (TEP+GEF 8.3% vs CTx 57.1%), neutrophil count decreased (TEP+GEF 0% vs CTx 57.1%), and nausea (TEP+GEF 8.3% vs CTx 42.9%). Conclusions Promising antitumor activity with TEP+GEF was reported in patients with METamp, EGFR-mutant T790M- NSCLC and acquired resistance to 1st-line EGFR TKIs. No new safety signals were observed. METamp can be considered a biomarker for tepotinib that should be further explored. Citation Format: James Chih-Hsin Yang, Jianying Zhou, Dong-Wan Kim, Azura Rozila Ahmad, Ross Andrew Soo, Rolf Bruns, Josef Straub, Andreas Johne, Jürgen Scheele, Keunchil Park, Yi-Long Wu. Tepotinib + gefitinib vs chemotherapy in MET-amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT193.

149PD Association Between Early Tumour Shrinkage (ETS) and Outcomes in RAS-wild Type (WT) Patients (pts) with Metastatic Colorectal Cancer (mcrc) Receiving First-Line FOLFOX or FOLFIRI + Cetuximab Every Other Week in the APEC Study

Impact of Primary Tumor Side (TS) on Outcomes of Once-Every-2-weeks (q2w) Cetuximab + First-Line (1L) FOLFOX or FOLFIRI in Patients with RAS Wild-Type (wt) Metastatic Colorectal Cancer (mcrc) in the Phase 2 APEC Trial.

Efficacy and Safety of Every-2-weeks Cetuximab Combined with FOLFOX or FOLFIRI As First-Line Therapy in Patients with KRAS Wild-Type Metastatic Colorectal Cancer (mcrc): an Asia-Pacific Nonrandomized Phase II Study (APEC).

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Phase II APEC Trial: the Impact of Primary Tumor Side on Outcomes of First‐line Cetuximab Plus FOLFOX or FOLFIRI in Patients with RAS Wild‐type Metastatic Colorectal Cancer

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line Folfox or Folfiri in Patients with Kras or All Ras Wild-Type Metastatic Colorectal Cancer: the Phase 2 Apec Study

Early Tumor Shrinkage As Predictor of Outcome in Colorectal Liver Metastases Treated with Cetuximab Plus Chemotherapy

Final Analysis of the Phase 2 Apec Study: Overall Survival (os) Data and Biomarker Subanalyses for First-Line Folfox or Folfiri with Cetuximab (cet) Once Every 2 Weeks in Patients (pts) with Kras or Ras (kras and Nras, Exons 2-4) Wild-Type (wt) Metastatic Colorectal Cancer (Mcrc).

Impact Of Primary Tumor Side On Outcomes Of Every-2-Weeks (Q2w) Cetuximab Plus First-Line Folfox Or Folfiri In Patients With Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) In The Phase 2 Apec Trial.

Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab.

First-Line Cetuximab with Folfox or Folfiri Every 2 Weeks in Kras Wild-Type Metastatic Colorectal Cancer: Phase II Apec Study

Abstract CT193: Tepotinib + gefitinib vs chemotherapy in<i>MET-</i>amplified EGFR-mutant non-small cell lung cancer (NSCLC): Predefined subgroup analysis of a Phase Ib/II study

Quality of Life (qol) Analyses in Patients with RAS Wild-Type (wt) Metastatic Colorectal Cancer (mcrc) Treated with First-Line FOLFOX-4 ± Cetuximab in the Phase 3 TAILOR Trial

Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial

Impact of Primary Tumour Side on 3-Year Survival Outcomes of First-Line (1L) FOLFOX-4 ± Cetuximab in Patients with RAS Wild-Type (wt) Metastatic Colorectal Cancer (mcrc) in the Phase III TAILOR Trial

Impact of early tumor shrinkage and depth of response in patients with BRAF V600E-mutant metastatic colorectal cancer.

169P First-line FOLFOX-4 6 Cetuximab in Patients with RAS Wild- Type Metastatic Colorectal Cancer: the Open-Label, Randomized, Phase 3 TAILOR Trial

Associations between AI-Assisted Tumor Amphiregulin and Epiregulin IHC and Outcomes from Anti-EGFR Therapy in the Routine Management of Metastatic Colorectal Cancer

High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.

Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.